Risk factors for refractory respiratory distress syndrome among very-low-birth-weight infants.
Humans
Respiratory Distress Syndrome, Newborn
/ epidemiology
Infant, Newborn
Female
Risk Factors
Male
Infant, Very Low Birth Weight
Pulmonary Surfactants
/ therapeutic use
Republic of Korea
/ epidemiology
Gestational Age
Cesarean Section
/ statistics & numerical data
Apgar Score
Retrospective Studies
Logistic Models
Preeclampsia
Pregnancy-induced hypertension
Respiratory distress syndrome
Surfactant
Very-low-birth-weight infant
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
received:
03
07
2024
accepted:
07
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
The objective was to evaluate refractory respiratory distress syndrome (RDS) risk factors among very-low-birth-weight infants (VLBWIs). The data of VLBWIs born between January 2013 and December 2020 registered in the Korean Neonatal Network (KNN) were analyzed. Infants who died within 5 postnatal days or who were not given surfactant were excluded. Infants were divided into a well-responding RDS group, which received surfactant replacement therapy (SRT) only once, and a refractory RDS group, which received SRT twice or more. The associations between perinatal characteristics and refractory RDS were investigated via multivariate logistic regression analysis. Multivariate logistic regression analysis revealed that low gestational age (adjusted odds ratio [aOR] = 1.26, 95% confidence interval (CI) [1.23, 1.26], male sex (aOR = 1.17, 95% CI [1.06, 1.29]), cesarean section (aOR = 1.59, 95% CI [1.38, 1.80]), maternal hypertensive disorder (aOR = 1.54, 95% CI[1.35, 1.75]), and low 5-minute Apgar scores (aOR = 1.24, 95% CI [1.12, 1.37]) were significantly associated with refractory RDS. Antenatal corticosteroid use (aOR = 0.81, 95% CI [0.73, 0.89]) and maternal chorioamnionitis (aOR = 0.79, 95% CI [0.71, 0.88]) were significantly inversely associated with refractory RDS. Compared with well-responding RDS, refractory RDS was significantly associated with increased major neonatal morbidity and mortality risk at 5 postnatal days. Maternal hypertensive disorder is a significant risk factor for refractory RDS. Refractory RDS was associated with unfavorable neonatal outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The objective was to evaluate refractory respiratory distress syndrome (RDS) risk factors among very-low-birth-weight infants (VLBWIs).
METHOD
METHODS
The data of VLBWIs born between January 2013 and December 2020 registered in the Korean Neonatal Network (KNN) were analyzed. Infants who died within 5 postnatal days or who were not given surfactant were excluded. Infants were divided into a well-responding RDS group, which received surfactant replacement therapy (SRT) only once, and a refractory RDS group, which received SRT twice or more. The associations between perinatal characteristics and refractory RDS were investigated via multivariate logistic regression analysis.
RESULTS
RESULTS
Multivariate logistic regression analysis revealed that low gestational age (adjusted odds ratio [aOR] = 1.26, 95% confidence interval (CI) [1.23, 1.26], male sex (aOR = 1.17, 95% CI [1.06, 1.29]), cesarean section (aOR = 1.59, 95% CI [1.38, 1.80]), maternal hypertensive disorder (aOR = 1.54, 95% CI[1.35, 1.75]), and low 5-minute Apgar scores (aOR = 1.24, 95% CI [1.12, 1.37]) were significantly associated with refractory RDS. Antenatal corticosteroid use (aOR = 0.81, 95% CI [0.73, 0.89]) and maternal chorioamnionitis (aOR = 0.79, 95% CI [0.71, 0.88]) were significantly inversely associated with refractory RDS. Compared with well-responding RDS, refractory RDS was significantly associated with increased major neonatal morbidity and mortality risk at 5 postnatal days.
CONCLUSION
CONCLUSIONS
Maternal hypertensive disorder is a significant risk factor for refractory RDS. Refractory RDS was associated with unfavorable neonatal outcomes.
Identifiants
pubmed: 39448962
doi: 10.1186/s12887-024-05138-7
pii: 10.1186/s12887-024-05138-7
doi:
Substances chimiques
Pulmonary Surfactants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677Informations de copyright
© 2024. The Author(s).
Références
Eras Z, Zeybek C, Akansel R, Yildirim S, Simsek DG, Turkyilmaz C, et al. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome. Am J Perinatol. 2014;31(6):463–8.
pubmed: 23884719
Condò V, Cipriani S, Colnaghi M, Bellù R, Zanini R, Bulfoni C, et al. Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? J Matern Fetal Neonatal Med. 2017;30(11):1267–72.
doi: 10.1080/14767058.2016.1210597
pubmed: 27399933
Bancalari E. Antenatal infections and respiratory outcome in preterm infants. Am J Perinatol. 2020;37:S02.
Bryan H, Kennedy KI, Shine W. Perinatal factors associated with the respiratory distress syndrome. Am J Obstet Gynecol. 1990;162(2):476–81.
doi: 10.1016/0002-9378(90)90415-4
pubmed: 2309834
McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12.
Ma CC, Ma S. The role of surfactant in respiratory distress syndrome. Open Respir Med J. 2012;6:44–53.
doi: 10.2174/1874306401206010044
pubmed: 22859930
pmcid: 3409350
Carnielli VP, Zimmermann LJ, Hamvas A, Cogo PE. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. J Perinatol. 2009;29:S2.
doi: 10.1038/jp.2009.32
Lacaze-Masmonteil T. Une nouvelle génération de surfactants de synthèse. Arch Pediatr. 2008;15(Suppl 2).
Mavis RD, Finkelstein JN, Hall BP. Pulmonary surfactant synthesis. A highly active microsomal phosphatidate phosphohydrolase in the lung. J Lipid Res. 1978;19(4):467–77.
doi: 10.1016/S0022-2275(20)40718-7
pubmed: 207801
Bancalari E, del Moral T. Bronchopulmonary dysplasia and surfactant. Neonatology. 2001;80(1):7–13.
doi: 10.1159/000047170
Koivisto M, Marttila R, Kurkinen-Räty M, Heinonen K, Hallman M. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990s: a population-based survey. Acta Paediatr. 2004;93(2):177–84.
doi: 10.1111/j.1651-2227.2004.tb00702.x
pubmed: 15046270
Dani C, Poggi C, Bertini G, Pratesi S, Di Tommaso M, Scarselli G. Risk factors for the development of respiratory distress syndrome and transient tachypnoea in newborn infants. Eur Respir J. 1999;14(1):155–9.
doi: 10.1034/j.1399-3003.1999.14a26.x
pubmed: 10489844
Yoon JJ, Kohl S, Harper RG. The relationship between maternal hypertensive disease of pregnancy and the incidence of idiopathic respiratory distress syndrome. Pediatrics. 1980;65(4):735–9.
doi: 10.1542/peds.65.4.735
pubmed: 7367080
Zimmermann LJ, Janssen DJ, Tibboel D, Hamvas A, Carnielli VP. Surfactant metabolism in the neonate. Neonatology. 2005;87(4):296–307.
doi: 10.1159/000084877
Taeusch HW, Keough KM. Inactivation of pulmonary surfactant and the treatment of acute lung injuries. Pediatr Pathol Mol Med. 2001;20(6):519–36.
doi: 10.1080/pdp.20.6.519.536
pubmed: 11699577
Robertson B. Surfactant inactivation and surfactant therapy in acute respiratory distress syndrome (ARDS). Monaldi Arch Chest Dis. 1998;53(1):64–9.
pubmed: 9632910
Duggan M, Kavanagh BP. Atelectasis. In: Wilmott RW, Boat TF, Bush A, Chernick V, Deterding RR, Ratjen FA, editors. Kendig and Chernick’s disorders of the respiratory tract in children. 8th ed. Philadelphia: W.B. Saunders; 2012. pp. 564–9.
doi: 10.1016/B978-1-4377-1984-0.00037-1
Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 2017;41(6):387–91.
doi: 10.1053/j.semperi.2017.07.009
pubmed: 28865982
Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019;7:2050312119843700.
doi: 10.1177/2050312119843700
pubmed: 31007914
pmcid: 6458675
Reddy S, Jim B. Hypertension and pregnancy: management and future risks. Adv Chronic Kidney Dis. 2019;26(2):137–45.
doi: 10.1053/j.ackd.2019.03.017
pubmed: 31023448
Bendix I, Miller SL, Winterhager E. Editorial: causes and consequences of intrauterine growth restriction. Front Endocrinol (Lausanne). 2020;11:205.
doi: 10.3389/fendo.2020.00205
pubmed: 32351451
Tsakiridis I, Giouleka S, Mamopoulos A, Kourtis A, Athanasiadis A, Dagklis T. Chronic hypertension in pregnancy: synthesis of influential guidelines. J Perinat Med. 2021;49(7):859–72.
doi: 10.1515/jpm-2021-0015
pubmed: 33872475
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022;79(2).
Wen YH, Lee CH, Lin HL, Lin HC, Lee MS, Chen CL, et al. Association of maternal preeclampsia with neonatal respiratory distress syndrome in very-low-birth-weight infants. Sci Rep. 2019;9(1):13212.
doi: 10.1038/s41598-019-49561-8
pubmed: 31519996
pmcid: 6744454
Langenveld J, Ravelli AC, van Kaam AH, van der Ham DP, van Pampus MG, Porath MM, et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol. 2011;205(6):e5401–7.
doi: 10.1016/j.ajog.2011.07.003
Tian T, Wang L, Ye R, Liu J, Ren A. Maternal hypertension, preeclampsia, and risk of neonatal respiratory disorders in a large prospective cohort study. Pregnancy Hypertens. 2020;19:131–7.
doi: 10.1016/j.preghy.2020.01.006
pubmed: 31982835
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. Obstet Gynecol Surv. 2016;71(5):273–4.
doi: 10.1097/01.ogx.0000482523.79556.f6
Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol. 1995;172(6):1785–92.
doi: 10.1016/0002-9378(95)91412-9
pubmed: 7778633
Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8(7):702–10.
doi: 10.1038/nm721
pubmed: 12053176
Goss KN. Long-term pulmonary vascular consequences of perinatal insults. J Physiol. 2019;597(4):1175–84.
doi: 10.1113/JP275859
pubmed: 30067297
Bokslag A, van Weissenbruch M, Mol BW, de Groot CJ. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 2016;102:47–50.
doi: 10.1016/j.earlhumdev.2016.09.007
pubmed: 27659865
Tang Y, Yu Y, Zhang S, Bao L, Xu C, Li H, et al. VEGF and sFLT-1 in serum of PIH patients and effects on the foetus. Exp Ther Med. 2019;17(3):2123–8.
pubmed: 30867699
pmcid: 6396009